Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Plus Sintilimab and Modified XELOX in Unresectable Locally Advanced Gastric Cancer
NCT07638631Phase 2Not yet recruiting
- Sponsor
- Wondfo
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in gastric cancer (GC), sponsored by Wondfo. Primary endpoint: Surgical Conversion Rate at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ipilimumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07638631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638631.